The 20th Anniversary of Pegaptanib (MacugenTM), the First Approved Aptamer Medicine: History, Recent Advances and Future Prospects of Aptamers in Therapy DOI Creative Commons
Miklós Bege, Rasha Ghanem Kattoub, Anikó Borbás

et al.

Pharmaceutics, Journal Year: 2025, Volume and Issue: 17(3), P. 394 - 394

Published: March 20, 2025

In addition to classic small-molecule drugs and modern protein-based biologics, an intriguing class of medicines is the therapeutic oligonucleotides. Most approved in this category are antisense oligomers or those acting via RNA interference, both which use base hybridization. Aptamers, also known as chemical antibodies form a smaller, yet equally interesting group oligonucleotides that can recognize wide range molecular targets. Despite their high potential, only two aptamers have been date, pegaptanib (MacugenTM) avacincaptad pegol (IzervayTM), for treatment age-related macular degeneration (AMD). Targeting vascular endothelial growth factor (VEGF), plays important role pathogenesis many eye diseases, emerged first anti-VEGF agent was used various indications, further inspiring development other therapies. review, we summarize history aptamer medicine, pegaptanib. We describe its chemistry track from earliest stages preclinical phase, clinical trials, eventual regulatory approval. Additionally, evaluate position among agents provide comprehensive overview pegaptanib’s efficacy, safety, cost-effectiveness, comparing these aspects with monoclonal similar bevacizumab ranibizumab.

Language: Английский

The 20th Anniversary of Pegaptanib (MacugenTM), the First Approved Aptamer Medicine: History, Recent Advances and Future Prospects of Aptamers in Therapy DOI Creative Commons
Miklós Bege, Rasha Ghanem Kattoub, Anikó Borbás

et al.

Pharmaceutics, Journal Year: 2025, Volume and Issue: 17(3), P. 394 - 394

Published: March 20, 2025

In addition to classic small-molecule drugs and modern protein-based biologics, an intriguing class of medicines is the therapeutic oligonucleotides. Most approved in this category are antisense oligomers or those acting via RNA interference, both which use base hybridization. Aptamers, also known as chemical antibodies form a smaller, yet equally interesting group oligonucleotides that can recognize wide range molecular targets. Despite their high potential, only two aptamers have been date, pegaptanib (MacugenTM) avacincaptad pegol (IzervayTM), for treatment age-related macular degeneration (AMD). Targeting vascular endothelial growth factor (VEGF), plays important role pathogenesis many eye diseases, emerged first anti-VEGF agent was used various indications, further inspiring development other therapies. review, we summarize history aptamer medicine, pegaptanib. We describe its chemistry track from earliest stages preclinical phase, clinical trials, eventual regulatory approval. Additionally, evaluate position among agents provide comprehensive overview pegaptanib’s efficacy, safety, cost-effectiveness, comparing these aspects with monoclonal similar bevacizumab ranibizumab.

Language: Английский

Citations

0